PTC INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $PTC in the last 30 days.
See all $PTC insider activity →Shares of Braze, Procore, PTC, Samsara, and Zeta Global rose after strong earnings reports and positive AI-driven growth commentary from major tech firms. Salesforce, CrowdStrike, and Okta showed AI boosted product adoption and revenue. Braze's stock surged 10%, trading near its 52-week high.
PTC Therapeutics will acquire ST-920, a gene therapy for Fabry disease, from Sangamo Therapeutics for $111M upfront and up to $100M in milestones. PTC plans to seek FDA accelerated approval in 2023, with a potential 2027 launch. The therapy showed kidney function improvements in clinical trials.
PTC Therapeutics presented new data on Sephience (sepiapterin) at the 2026 SSIEM Symposium, showing sustained metabolic control, diet liberalization, and a favorable safety profile in PKU patients. Key findings include a 100% greater reduction in blood Phe for participants on sapropterin and clinically meaningful reductions in high baseline Phe levels. Sephience is approved in the U.S., EU, Japan, and other countries for PKU treatment.
Over the past 7 days, alphai's AI scored 4 news stories mentioning PTC (PTC INC.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 1 bearish.
Recent PTC coverage spans sector analysis, financial news and market movers.
Moderate rally tied to sector sentiment.
Potential upside from adding a rare‑disease gene therapy to PTC's pipeline and upcoming FDA accelerated filing.
Positive trial data may boost investor confidence and support price appreciation.
Reputational risk for PTC could affect enterprise sales.
Analyst upgrade with higher price targets may support upside potential.
alphai scores every news story that mentions PTC with an AI model for sentiment and relevance, and aggregates insider trades from PTC INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Shares of Braze, Procore, PTC, Samsara, and Zeta Global rose after strong earnings reports and positive AI-driven growth commentary from major tech firms. Salesforce, CrowdStrike, and Okta showed AI boosted product adoption and revenue. Braze's stock surged 10%, trading near its 52-week high.
2 min readPTC Therapeutics will acquire ST-920, a gene therapy for Fabry disease, from Sangamo Therapeutics for $111M upfront and up to $100M in milestones. PTC plans to seek FDA accelerated approval in 2023, with a potential 2027 launch. The therapy showed kidney function improvements in clinical trials.
2 min readPTC Therapeutics presented new data on Sephience (sepiapterin) at the 2026 SSIEM Symposium, showing sustained metabolic control, diet liberalization, and a favorable safety profile in PKU patients. Key findings include a 100% greater reduction in blood Phe for participants on sapropterin and clinically meaningful reductions in high baseline Phe levels. Sephience is approved in the U.S., EU, Japan, and other countries for PKU treatment.
2 min readOracle, NetScaler, GitLab, Microsoft, and SAP released critical security patches to address vulnerabilities. GitLab and SAP flaws are being actively exploited. Cl0p claims to have stolen data from Shell via a PTC flaw. Infostealers and mobile fraud threats emerged, including MacSync Stealer and Android NFC fraud. LiteLLM compromise exposed credentials. AI-assisted attacks targeted cryptocurrency users and Taiwan government systems, with AI agents showing destructive behavior.
3 min readBarclays analyst Saket Kalia kept a 'Buy' rating and $155 price target on PTC. The average target is $172.90, implying 16.4% upside, while the highest target is $230, suggesting 54.8% potential gain. The ratings have not changed in the past three months.
1 min readPTC India Limited said its 27th AGM will be held Sept 30, 2026 at 12:30 PM via video conferencing. The company set Oct 7, 2026 as the record date for the proposed final dividend for FY 2025-26. The board recommended a 55% final dividend, Rs 5.50 per equity share of Rs 10, according to the company.
2 min readPTC Industries shares fell about 4% after reporting Q1 FY27 results. According to the company, profit rose 466% year over year to ₹29.1 crore and EBITDA increased 180% to ₹54.2 crore. Revenue grew 83% to ₹197.1 crore, supported by aerospace and defence programmes, with Aerolloy Technologies as a key driver.
2 min readA study of Q1 FY27 results for India’s NIFTY 500 shows 67 firms had net profit growth over 100% versus revenue growth in April to June, according to ACE Equity. The article highlights five companies where profit rose faster than revenue: Neuland Laboratories, CreditAccess Grameen, Leela Palace Hotels, Devyani International, and PTC Industries, with figures including Neuland profit up 962% to ₹148 crore and PTC profit up 466% to ₹292 crore.
3 min readPTC Industries Ltd reported Q1 FY27 results for the quarter ended June 30, 2026, citing higher advanced manufacturing contributions. Its wholly owned unit Aerolloy Technologies (ATL) posted total income of ₹742.7m vs ₹131.1m in Q1 FY26, EBITDA ₹334.2m (45% margin), and PAT ₹220.8m (+322.9% YoY). ATL signed an Airbus agreement for titanium castings for A320neo, A330neo and A350, and PTC received defence orders from BrahMos Aerospace, ARDE-DRDO and Gun Factory Kanpur.
3 min readCybercrime group Clop claims it stole data from more than 40 companies, including Shell and General Electric, and lists firms such as Philips, Fiserv, and Toast. The article cites denials from Toast and Fiserv that customer or personal data was taken, and Shell says access was blocked with no operational impact. It links Clop to a July PTC Windchill/FlexPLM flaw (CVE-2026-12569).
7 min read
